Euglycemic diabetic ketoacidosis (euglycemic DKA) is treated with the same core approach as standard DKA: intravenous fluids, insulin, and electrolyte replacement. The critical difference is that because blood sugar is already below 250 mg/dL, dextrose (sugar-containing fluid) must be started alongside insulin from the beginning of treatment to prevent dangerously low blood sugar while the insulin works to shut down ketone production. This makes treatment trickier than standard DKA, where clinicians have a wider glucose margin to work with.
Why Euglycemic DKA Is Easy to Miss
In standard DKA, blood sugar spikes above 250 mg/dL and often well beyond 400 mg/dL, making the diagnosis straightforward. Euglycemic DKA produces the same dangerous acid buildup and ketone surge, but blood glucose stays under 250 mg/dL. The diagnosis requires a blood pH below 7.3, serum bicarbonate below 18 mEq/L, and elevated ketones in blood or urine. Lactic acid may also be elevated but should not fully explain the high anion gap.
The most common modern trigger is SGLT2 inhibitor medications, which lower blood sugar by forcing the kidneys to excrete glucose in urine. This glucose-lowering effect masks the hyperglycemia that would normally signal DKA, while the body simultaneously shifts toward burning fat and producing ketones. Other triggers include pregnancy, prolonged fasting or very low carbohydrate intake, heavy alcohol use, and acute illness in people with diabetes who have been eating poorly or vomiting.
Intravenous Fluids Come First
Aggressive fluid resuscitation is the first step. Patients in DKA are typically severely dehydrated, often with fluid deficits of several liters. Normal saline is the standard initial fluid. The volume and rate depend on how dehydrated the patient is, their heart and kidney function, and their blood pressure. Restoring fluid volume improves circulation, helps the kidneys clear ketones, and dilutes the acid in the bloodstream.
Insulin Plus Dextrose: The Balancing Act
Insulin is the treatment that actually stops ketone production and reverses the acidosis. In standard DKA, insulin is started and dextrose is added later, once blood sugar drops below 200 to 250 mg/dL. In euglycemic DKA, blood sugar is already in that range or lower, so dextrose-containing fluids need to run from the start. This creates a deliberate balancing act: insulin is given to suppress ketone production, while dextrose keeps blood sugar from falling to dangerous levels.
The goal is not to raise blood sugar. The goal is to maintain a safe glucose level (typically around 150 to 200 mg/dL) while insulin does its real job of clearing ketoacids. Blood sugar needs to be checked frequently, often every one to two hours, so the dextrose rate can be adjusted. This is why euglycemic DKA almost always requires an intensive care or step-down unit setting with close monitoring.
Potassium and Electrolyte Replacement
Potassium replacement is a non-negotiable part of DKA treatment. Insulin drives potassium from the bloodstream into cells, which can cause a sudden and dangerous drop in blood potassium levels. If potassium falls too low, it can trigger life-threatening heart rhythm problems. If the potassium level is below 3.3 mEq/L, insulin must be held entirely until potassium is replaced, typically at 20 to 30 mEq per hour. Even when potassium is in the normal range, replacement is usually added to IV fluids because levels will drop once insulin starts working.
Magnesium and phosphate levels also tend to fall during DKA treatment and are monitored and replaced as needed.
How Clinicians Know It’s Resolving
Treatment continues until the ketoacidosis clears, not until blood sugar reaches a certain number. A 2024 consensus report from the American Diabetes Association and the European Association for the Study of Diabetes defines resolution as blood ketones below 0.6 mmol/L with a venous pH at or above 7.3 or bicarbonate at or above 18 mmol/L. Blood sugar should ideally also be below 200 mg/dL, though in euglycemic DKA it may already be well under that threshold throughout treatment.
Once these targets are met and the patient can eat, the transition from intravenous to injectable (subcutaneous) insulin begins. This is a vulnerable window. The IV insulin drip should continue for one to two hours after the first subcutaneous dose to prevent a rebound into ketoacidosis. Stopping the drip too soon is a common cause of DKA relapse in the hospital.
Addressing the Underlying Trigger
Reversing the acidosis is only half the job. The trigger that caused the euglycemic DKA needs to be identified and managed to prevent recurrence. If an SGLT2 inhibitor is the cause, the medication is stopped immediately and may be permanently discontinued depending on the clinical picture. Any underlying infection, dehydration, or missed insulin doses need to be addressed. In pregnancy-related cases, close coordination between endocrinology and obstetrics is essential because ketoacidosis carries serious risks for both the mother and fetus.
Preventing Euglycemic DKA
For people taking SGLT2 inhibitors, the most important prevention strategy centers on surgery and illness. The American Diabetes Association recommends stopping most SGLT2 inhibitors at least three days before any scheduled procedure. Ertugliflozin should be stopped four days before. The mnemonic used by safety organizations is SSTOP: Stop SGLT2 inhibitors Three days before Procedures.
During any acute illness that involves vomiting, reduced food intake, or dehydration, SGLT2 inhibitors should also be paused. Patients on these medications who develop nausea, abdominal pain, fatigue, or rapid breathing should have their ketone levels checked even if their blood sugar looks normal. The normal glucose reading is exactly what makes this condition deceptive, and catching it early makes treatment faster and less complicated.